Oncology Impact Fund (cayman) Management L.p. - Net Worth and Insider Trading

Oncology Impact Fund (cayman) Management L.p. Net Worth

The estimated net worth of Oncology Impact Fund (cayman) Management L.p. is at least $238 Million dollars as of 2024-05-12. Oncology Impact Fund (cayman) Management L.p. is the 10% Owner of Cullinan Therapeutics Inc and owns about 7,648,268 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $203 Million. Oncology Impact Fund (cayman) Management L.p. is the 10% Owner of Harpoon Therapeutics Inc and owns about 1,278,514 shares of Harpoon Therapeutics Inc (HARP) stock worth over $29 Million. Oncology Impact Fund (cayman) Management L.p. is also the 10% Owner of TCR2 Therapeutics Inc and owns about 3,370,982 shares of TCR2 Therapeutics Inc (TCRR) stock worth over $5 Million. Besides these, Oncology Impact Fund (cayman) Management L.p. also holds Oncorus Inc (ONCR) . Details can be seen in Oncology Impact Fund (cayman) Management L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Oncology Impact Fund (cayman) Management L.p. has not made any transactions after 2021-09-16 and currently still holds the listed stock(s).

Transaction Summary of Oncology Impact Fund (cayman) Management L.p.

Oncology Impact Fund (cayman) Management L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Oncology Impact Fund (cayman) Management L.p. owns 10 companies in total, including Oncorus Inc (ONCR) , ITeos Therapeutics Inc (ITOS) , and TCR2 Therapeutics Inc (TCRR) among others .

Click here to see the complete history of Oncology Impact Fund (cayman) Management L.p.’s form 4 insider trades.

Insider Ownership Summary of Oncology Impact Fund (cayman) Management L.p.

Ticker	Comapny	Transaction Date	Type of Owner
ONCR	Oncorus Inc	2020-10-06	10 percent owner
ITOS	ITeos Therapeutics Inc	2020-07-23	other: X*
TCRR	TCR2 Therapeutics Inc	2019-02-19	10 percent owner
		2021-05-27	10 percent owner
		2017-11-02	10 percent owner
		2017-03-25	10 percent owner
		2017-10-27	10 percent owner
		2017-03-25	10 percent owner
		2021-04-29	10 percent owner
		2021-09-16	10 percent owner

Oncology Impact Fund (cayman) Management L.p. Latest Holdings Summary

Oncology Impact Fund (cayman) Management L.p. currently owns a total of 4 stocks. Among these stocks, Oncology Impact Fund (cayman) Management L.p. owns 7,648,268 shares of Cullinan Therapeutics Inc (CGEM) as of September 16, 2021, with a value of $203 Million and a weighting of 85.41%. Oncology Impact Fund (cayman) Management L.p. owns 1,278,514 shares of Harpoon Therapeutics Inc (HARP) as of May 27, 2021, with a value of $29 Million and a weighting of 12.36%. Oncology Impact Fund (cayman) Management L.p. also owns 3,370,982 shares of TCR2 Therapeutics Inc (TCRR) as of February 19, 2019, with a value of $5 Million and a weighting of 2.1%. The other 1 stocks Oncorus Inc (ONCR) have a combined weighting of 0.13% among all his current holdings.

Latest Holdings of Oncology Impact Fund (cayman) Management L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CGEM	Cullinan Therapeutics Inc	2021-09-16	7,648,268	26.57	203,214,481
HARP	Harpoon Therapeutics Inc	2021-05-27	1,278,514	23.01	29,418,607
TCRR	TCR2 Therapeutics Inc	2019-02-19	3,370,982	1.48	4,989,053
ONCR	Oncorus Inc	2020-10-06	2,377,025	0.13	299,505

Holding Weightings of Oncology Impact Fund (cayman) Management L.p.

Oncology Impact Fund (cayman) Management L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Oncology Impact Fund (cayman) Management L.p. has made a total of 9 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 1 buys and 8 sells. The most-recent trade in Cullinan Therapeutics Inc is the sale of 3,124 shares on September 16, 2021, which brought Oncology Impact Fund (cayman) Management L.p. around $90,783.

According to the SEC Form 4 filings, Oncology Impact Fund (cayman) Management L.p. has made a total of 11 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in Harpoon Therapeutics Inc is the sale of 1,716 shares on May 27, 2021, which brought Oncology Impact Fund (cayman) Management L.p. around $346,955.

According to the SEC Form 4 filings, Oncology Impact Fund (cayman) Management L.p. has made a total of 0 transactions in TCR2 Therapeutics Inc (TCRR) over the past 5 years. The most-recent trade in TCR2 Therapeutics Inc is the acquisition of 666,667 shares on February 19, 2019, which cost Oncology Impact Fund (cayman) Management L.p. around $10 Million.

More details on Oncology Impact Fund (cayman) Management L.p.'s insider transactions can be found in the Insider Trading History of Oncology Impact Fund (cayman) Management L.p. table.

Insider Trading History of Oncology Impact Fund (cayman) Management L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Oncology Impact Fund (cayman) Management L.p. Trading Performance

GuruFocus tracks the stock performance after each of Oncology Impact Fund (cayman) Management L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Oncology Impact Fund (cayman) Management L.p. is 22.45%. GuruFocus also compares Oncology Impact Fund (cayman) Management L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Oncology Impact Fund (cayman) Management L.p. within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Oncology Impact Fund (cayman) Management L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Oncology Impact Fund (cayman) Management L.p.

Average Return

Average return per transaction

Outperforming Transactions

1 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	18.56
Relative Return to S&P 500(%)	15.68

Oncology Impact Fund (cayman) Management L.p. Ownership Network

Ownership Network List of Oncology Impact Fund (cayman) Management L.p.

No Data

Ownership Network Relation of Oncology Impact Fund (cayman) Management L.p.

Oncology Impact Fund (cayman) Management L.p. Owned Company Details

What does Oncorus Inc do?

Who are the key executives at Oncorus Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and director & 10 percent owner & other: *Possible Member of 10% Group James E Flynn .

Oncorus Inc (ONCR) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in Oncorus Inc (ONCR). Other recent insider transactions involving Oncorus Inc (ONCR) include a net sale of 551,663 shares made by James E Flynn ,

In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 551,663 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 551,663 shares.

Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oncorus Inc Insider Transactions

No Available Data

What does ITeos Therapeutics Inc do?

Who are the key executives at ITeos Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the other: X* of ITeos Therapeutics Inc. Other key executives at ITeos Therapeutics Inc include Chief Financial Officer Matthew Gall , other: See remarks Joseph Lewis , and other: See remarks Boxer Asset Management Inc. .

ITeos Therapeutics Inc (ITOS) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in ITeos Therapeutics Inc (ITOS). Other recent insider transactions involving ITeos Therapeutics Inc (ITOS) include a net sale of 350,000 shares made by Boxer Capital, Llc , and a net purchase of 5,000 shares made by Matthew Gall .

In summary, during the past 3 months, insiders sold 0 shares of ITeos Therapeutics Inc (ITOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 350,000 shares of ITeos Therapeutics Inc (ITOS) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 345,000 shares.

ITeos Therapeutics Inc (ITOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

ITeos Therapeutics Inc Insider Transactions

No Available Data

What does TCR2 Therapeutics Inc do?

Who are the key executives at TCR2 Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of TCR2 Therapeutics Inc. Other key executives at TCR2 Therapeutics Inc include 10 percent owner Kevin C Tang , director & 10 percent owner Ansbert Gadicke , and 10 percent owner Mpm Asset Management Llc .

TCR2 Therapeutics Inc (TCRR) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in TCR2 Therapeutics Inc (TCRR). Other recent insider transactions involving TCR2 Therapeutics Inc (TCRR) include a net purchase of 468,513 shares made by Kevin C Tang , a net sale of 82,187 shares made by Garry E Menzel , and a net sale of 32,841 shares made by Alfonso Quintas Cardama .

In summary, during the past 3 months, insiders sold 0 shares of TCR2 Therapeutics Inc (TCRR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 287,401 shares of TCR2 Therapeutics Inc (TCRR) were sold and 468,513 shares were bought by its insiders, resulting in a net purchase of 181,112 shares.

TCR2 Therapeutics Inc (TCRR)'s detailed insider trading history can be found in Insider Trading Tracker table.

TCR2 Therapeutics Inc Insider Transactions

No Available Data

What does Harpoon Therapeutics Inc do?

Who are the key executives at Harpoon Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Harpoon Therapeutics Inc. Other key executives at Harpoon Therapeutics Inc include 10 percent owner Vijay K Lathi , Chief Medical Officer Luke Nathaniel Walker , and Principal Fin. & Acctng Ofc. Frank J Lanza .

Harpoon Therapeutics Inc (HARP) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in Harpoon Therapeutics Inc (HARP). Other recent insider transactions involving Harpoon Therapeutics Inc (HARP) include a net purchase of 21,397,205 shares made by Merck & Co., Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Harpoon Therapeutics Inc (HARP) in total and bought 21,397,205 shares, with a net purchase of 21,397,205 shares. During the past 18 months, 0 shares of Harpoon Therapeutics Inc (HARP) were sold and 21,397,205 shares were bought by its insiders, resulting in a net purchase of 21,397,205 shares.

Harpoon Therapeutics Inc (HARP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Harpoon Therapeutics Inc Insider Transactions

No Available Data

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks Judith A. Fox .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Spring Bank Pharmaceuticals Inc do?

Who are the key executives at Spring Bank Pharmaceuticals Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Spring Bank Pharmaceuticals Inc. Other key executives at Spring Bank Pharmaceuticals Inc include VP of Finance and Treasurer Lori Firmani , director & President and CEO Martin J Driscoll , and Chief Scientific Officer Radhakrishnan P. Iyer .

Spring Bank Pharmaceuticals Inc (SBPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spring Bank Pharmaceuticals Inc (SBPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Spring Bank Pharmaceuticals Inc (SBPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spring Bank Pharmaceuticals Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 21,403 shares made by Daniel R. Chevallard , a net sale of 4,272 shares made by Lisa Rojkjaer , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 3,405 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 3,405 shares. During the past 18 months, 25,675 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 74,325 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

What does F-star Therapeutics Inc do?

Who are the key executives at F-star Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of F-star Therapeutics Inc. Other key executives at F-star Therapeutics Inc include See Remarks Darlene M Deptula-hicks , CHIEF SCIENTIFIC OFFICER Neil Brewis , and CHIEF MEDICAL OFFICER Louis Kayitalire .

F-star Therapeutics Inc (FSTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of F-star Therapeutics Inc (FSTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of F-star Therapeutics Inc (FSTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

F-star Therapeutics Inc (FSTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

F-star Therapeutics Inc Insider Transactions

No Available Data

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Technology Officer Chulani Karunatilake , and Chief Operating Officer Reid Leonard .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in Werewolf Therapeutics Inc (HOWL). Other recent insider transactions involving Werewolf Therapeutics Inc (HOWL) include a net purchase of 1,853,000 shares made by Ra Capital Healthcare Fund Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Werewolf Therapeutics Inc (HOWL) were sold and 1,853,000 shares were bought by its insiders, resulting in a net purchase of 1,853,000 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

What does Cullinan Therapeutics Inc do?

Who are the key executives at Cullinan Therapeutics Inc?

Oncology Impact Fund (cayman) Management L.p. is the 10 percent owner of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include See Remarks Jennifer Michaelson , Acting Chief Business Officer Savill Corrine , and director & President and CEO Nadim Ahmed .

Cullinan Therapeutics Inc (CGEM) Insider Trades Summary

Over the past 18 months, Oncology Impact Fund (cayman) Management L.p. made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 83,555 shares made by Jennifer Michaelson , a net sale of 6,823 shares made by Jeffrey Trigilio , and a net sale of 3,809 shares made by Jeffrey Alan Jones .

In summary, during the past 3 months, insiders sold 63,606 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 63,606 shares. During the past 18 months, 224,214 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 224,214 shares.

Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cullinan Therapeutics Inc Insider Transactions

No Available Data

Oncology Impact Fund (cayman) Management L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Oncology Impact Fund (cayman) Management L.p.. You might contact Oncology Impact Fund (cayman) Management L.p. via mailing address: 450 Kendall Street, Cambridge Ma 02142.

Discussions on Oncology Impact Fund (cayman) Management L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.